NCT06747299

Brief Summary

Based on the PET/CT imaging data of patients with T-NK cell lymphoma, machine learning and deep learning methods are used to extract imaging features, establish a T-NK cell lymphoma prediction model, and provide more scientific and accurate prognosis prediction for the clinic.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
20mo left

Started Jan 2025

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress45%
Jan 2025Dec 2027

First Submitted

Initial submission to the registry

December 18, 2024

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 24, 2024

Completed
8 days until next milestone

Study Start

First participant enrolled

January 1, 2025

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

December 24, 2024

Status Verified

September 1, 2024

Enrollment Period

3 years

First QC Date

December 18, 2024

Last Update Submit

December 18, 2024

Conditions

T-NK Cell Lymphoma

Keywords

T-NK cell LymphomaPET/CTDiferential DiagnosisEfficacy PredictionPrognosis Prediction

Outcome Measures

Primary Outcomes (1)

  • Evaluation the value of Artificial Intelligence-based 18F-FDG PET/CT of T-NK Cell Lymphoma

    The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma

    Within 1 week of enrollment and after 3 months treatment

Secondary Outcomes (2)

  • Progress free survival

    3 years

  • Overall survival

    3 years

Study Arms (1)

patients diagnosis of T-NK cell lymphoma

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Pathological histology confirmed as T-NK Cell Lymphoma at Ruijin Hospital, Shanghai JiaoTong University School of Medicine

You may qualify if:

  • \. Pathological histology confirmed as T-NK Cell Lymphoma; 2.18F-FDG PET/CT examination before treatment; 3. Using modern best practice treatment options; 4. Complete clinicopathological and follow-up data were obtained.

You may not qualify if:

  • The patient had previously received antitumor therapy;
  • The patient had a history of other tumors;
  • Incomplete clinical information or imaging data;
  • Concomitant other malignant tumors.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine

Shanghai, Shanghai Municipality, China

Location

MeSH Terms

Conditions

Lymphoma, Extranodal NK-T-Cell

Condition Hierarchy (Ancestors)

Lymphoma, T-CellLymphoma, Non-HodgkinLymphomaNeoplasms by Histologic TypeNeoplasms

Central Study Contacts

Guo rui Deputy director

CONTACT

13361860108gr11734@rjh.com.cn

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Deputy director

Study Record Dates

First Submitted

December 18, 2024

First Posted

December 24, 2024

Study Start

January 1, 2025

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2027

Last Updated

December 24, 2024

Record last verified: 2024-09

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)